All patients
Age < 65y (younger) Age > 75y (older) Gender, female Gender, male metastasis (bone) metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% previous nephrectomy (no) previous nephrectomy (yes) Risk intermediate (IMDC) Risk poor (IMDC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced RCC (mRCC) - 1st line (L1), nivolumab plus ipilimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 214 (all population), 2017 0.68 [0.49; 0.95]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.45 [0.51; 4.12]
CheckMate 214 (intermediate and poor risk), 2017 0.63 [0.44; 0.90]
0.69 [0.53 ; 0.88 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 9% 2,192 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 214 (all population), 2017 0.71 [0.59; 0.86]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.22 [0.73; 2.04]
CheckMate 214 (intermediate and poor risk), 2017 0.66 [0.54; 0.80]
0.75 [0.59 ; 0.94 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 58% 2,192 moderate not evaluable PFS (extension)detailed results CheckMate 214 (all population), 2017 0.85 [0.73; 0.98]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.23 [0.90; 1.69]
CheckMate 214 (intermediate and poor risk), 2017 0.77 [0.65; 0.91]
0.89 [0.73 ; 1.09 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 70% 1,345 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 214 (all population), 2017 0.98 [0.79; 1.22]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 2.18 [1.29; 3.68]
CheckMate 214 (intermediate and poor risk), 2017 0.82 [0.64; 1.05]
1.12 [0.75 ; 1.68 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 82% 1,958 moderate not evaluable objective responses (ORR)detailed results CheckMate 214 (all population), 2017 1.35 [1.05; 1.73]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 0.64 [0.39; 1.07]
CheckMate 214 (intermediate and poor risk), 2017 1.98 [1.48; 2.64]
1.25 [0.75 ; 2.09 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 86% 2,192 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 214 (all population), 2017 1.36 [1.06; 1.74]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 0.64 [0.39; 1.07]
CheckMate 214 (intermediate and poor risk), 2017 1.70 [1.28; 2.26]
1.20 [0.78 ; 1.86 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 81% 2,192 moderate not evaluable TRAE (any grade)detailed results CheckMate 214 (all population), 2017 0.41 [0.22; 0.76]
0.41 [0.22 ; 0.76 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.39; 0.63]
0.49 [0.39 ; 0.63 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 214 (all population), 2017 1.97 [0.59; 6.58]
1.97 [0.59 ; 6.58 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 214 (all population), 2017 1.98 [1.42; 2.74]
1.98 [1.42 ; 2.74 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.31 [0.29; 5.86]
1.31 [0.29 ; 5.86 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 21.94 [1.29; 374.25]
21.94 [1.29 ; 374.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.08 [0.02; 0.35]
0.08 [0.02 ; 0.35 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.75 [0.33; 1.72]
0.75 [0.33 ; 1.72 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Blister TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.16 [0.01; 3.25]
0.16 [0.01 ; 3.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.04; 5.40]
0.49 [0.04 ; 5.40 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 21.94 [1.29; 374.25]
21.94 [1.29 ; 374.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.14 [0.38; 3.42]
1.14 [0.38 ; 3.42 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 11.86 [0.66; 212.80]
11.86 [0.66 ; 212.80 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.65 [0.37; 1.14]
0.65 [0.37 ; 1.14 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.02; 14.59]
0.49 [0.02 ; 14.59 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 39.87 [5.45; 291.45]
39.87 [5.45 ; 291.45 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.44 [0.26; 0.72]
0.44 [0.26 ; 0.72 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 0.84 [0.50; 1.43]
0.84 [0.50 ; 1.43 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 2.42 [1.41; 4.14]
2.42 [1.41 ; 4.14 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypertension TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.04 [0.01; 0.10]
0.04 [0.01 ; 0.10 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 3.92 [0.18; 87.20]
3.92 [0.18 ; 87.20 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 30.14 [1.80; 505.79]
30.14 [1.80 ; 505.79 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.18; 21.68]
1.96 [0.18 ; 21.68 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 2.86 [1.20; 6.83]
2.86 [1.20 ; 6.83 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 3.15 [1.47; 6.75]
3.15 [1.47 ; 6.75 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.61 [1.04; 2.49]
1.61 [1.04 ; 2.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 7.93 [0.99; 63.59]
7.93 [0.99 ; 63.59 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.06 [0.01; 0.48]
0.06 [0.01 ; 0.48 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.12 [0.40; 3.11]
1.12 [0.40 ; 3.11 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.02 [0.00; 0.13]
0.02 [0.00 ; 0.13 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 5.90 [0.29; 117.97]
5.90 [0.29 ; 117.97 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 17.88 [1.03; 309.26]
17.88 [1.03 ; 309.26 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 1.14 [0.38; 3.42]
1.14 [0.38 ; 3.42 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 11.86 [0.66; 212.80]
11.86 [0.66 ; 212.80 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 0.36 [0.21; 0.60]
0.36 [0.21 ; 0.60 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin hypopigmentation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.03 [0.00; 0.57]
0.03 [0.00 ; 0.57 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.02 [0.00; 0.34]
0.02 [0.00 ; 0.34 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.39 [0.12; 1.24]
0.39 [0.12 ; 1.24 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 15:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 79,178,152
- treatments: 416,864